The newer antipsychotic cariprazine (reagila): perspectives for use in different stages of schizophrenia therapy
Authors:
- 1 January 2021
- journal article
- review article
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 121 (9) , 139-144
Abstract
Cariprazine is a newer 3rd generation antipsychotic acting as partial agonist for dopamine receptors with unique higher affinity for D3 than D2 receptors. This review article summarizes key data from preclinical and clinical studies of cariprazine including pharmacodynamics, pharmacokinetics, clinical efficacy and safety/acceptability in acute short-term and long-term maintenance and relapse prevention therapy in patients with schizophrenia. Efficacy and safety of cariprazine in patients schizophrenia with predominantly negative symptoms resistant to previous antipsychotic therapy is discussed as well.Keywords
This publication has 31 references indexed in Scilit:
- Cariprazine in the treatment of schizophreniaInternational Clinical Psychopharmacology, 2016
- Cariprazine in Acute Exacerbation of SchizophreniaThe Journal of Clinical Psychiatry, 2015
- A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophreniaJournal of Psychopharmacology, 2015
- The ABC's of dopamine receptor partial agonists - aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents outInternational Journal Of Clinical Practice, 2015
- Efficacy and Safety of Cariprazine in Acute Exacerbation of SchizophreniaJournal of Clinical Psychopharmacology, 2015
- Relapse prevention study of paliperidone extended-release tablets in Chinese patients with schizophreniaProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2014
- An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: A phase II, randomized clinical trialSchizophrenia Research, 2014
- A Randomized Placebo-Controlled Trial of Asenapine for the Prevention of Relapse of Schizophrenia After Long-Term TreatmentThe Journal of Clinical Psychiatry, 2011
- A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic RelapseJournal of Clinical Psychopharmacology, 2003
- Aripiprazole for the Prevention of Relapse in Stabilized Patients With Chronic SchizophreniaThe Journal of Clinical Psychiatry, 2003